insiderwall
Menu
SuperinvestorInsider
Capricor Therapeutics Inc. CAPR

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases with high unmet medical needs, particularly Duchenne muscular dystrophy (DMD), which causes muscle degeneration and premature death. Its lead product candidate,

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees160
TickerCAPR

Statistics

Market Cap$1.63B
Revenue (TTM)$0
Net Income-$105.0M
Net Margin
EPS$-2.26
P/E-11.08
P/S
P/B5.24
EV/EBITDA-10.20
ROE-56.4%
Dividend Yield
Price$28.33

Data: Twelve Data · Revenue = mcap / P/S